Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size, Production, Sales, Average Product Price, Market Share, Import vs Export 

Expanding Therapeutic Horizons in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

The macular degeneration (AMD) and other retinal diseases drugs market is witnessing transformative growth as therapeutic modalities evolve to address a rising patient population affected by vision-impairing retinal disorders. For instance, the prevalence of age-related macular degeneration alone is projected to surpass 300 million people globally by 2040, significantly amplifying demand for innovative drugs. According to Datavagyanik, the macular degeneration (AMD) and other retinal diseases drugs market is benefiting from deeper understanding of disease pathways, leading to pipeline advancements such as complement inhibitors, gene therapies, and anti-VEGF biosimilars. This shift is reshaping treatment approaches, unlocking novel revenue streams, and expanding market participation for both traditional pharmaceutical companies and emerging biotech players. 

Anti-VEGF Therapies Driving Robust Revenue Growth in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Anti-VEGF therapies have cemented their position as the cornerstone of the macular degeneration (AMD) and other retinal diseases drugs market. For example, ranibizumab, aflibercept, and brolucizumab together generated billions in annual global sales over the last five years, reflecting their clinical and commercial success. Datavagyanik observes that as the treatment paradigm continues to shift toward long-acting formulations, the macular degeneration (AMD) and other retinal diseases drugs market is being reshaped by extended-dosing regimens that enhance patient adherence while reducing clinical burden. The introduction of port-delivery systems and refillable ocular implants exemplifies this transformative trend, signaling future disruption and driving sustained market expansion. 

Gene Therapy Fueling Innovation in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

In the macular degeneration (AMD) and other retinal diseases drugs market, gene therapy is rapidly emerging as a disruptive innovation with the potential to deliver one-time, durable treatments. For instance, adeno-associated virus (AAV)-based vectors are showing promising clinical outcomes, enabling sustained expression of anti-angiogenic proteins directly in retinal cells. Datavagyanik highlights that clinical-stage assets in gene therapy pipelines are progressing toward pivotal trials, with projected approvals anticipated over the coming five years. This innovation is expected to unlock significant market opportunities, expanding treatment options for patients with limited therapeutic alternatives. 

Biosimilars Intensifying Competition in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

As blockbuster anti-VEGF biologics approach patent expiry, the macular degeneration (AMD) and other retinal diseases drugs market is experiencing a surge in biosimilar launches. For example, ranibizumab biosimilars have already demonstrated price reductions of up to 30%, which is expected to stimulate broader patient access and fuel market growth. Datavagyanik believes that biosimilar adoption will not only drive competitive pricing but also catalyze a shift in prescriber preferences, thereby redefining the macular degeneration (AMD) and other retinal diseases drugs market landscape. This dynamic pricing environment will encourage more players to enter the market, intensifying innovation and expanding treatment reach. 

Rising Disease Prevalence Stimulating Demand in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

The macular degeneration (AMD) and other retinal diseases drugs market is propelled by the steep rise in retinal disease prevalence worldwide. For instance, diabetic retinopathy is anticipated to affect nearly 191 million people by 2030, creating enormous pressure on healthcare systems to deliver effective therapeutic solutions. Datavagyanik emphasizes that rising geriatric demographics, combined with increased incidence of diabetes and hypertension, are key factors amplifying the demand for retinal disease treatments. This confluence of risk factors is expected to propel the macular degeneration (AMD) and other retinal diseases drugs market, encouraging further R&D investments to develop superior therapeutics. 

Expanding Diagnostic Capabilities Empowering the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

The macular degeneration (AMD) and other retinal diseases drugs market is further strengthened by advances in retinal imaging and diagnostic technology. For example, optical coherence tomography (OCT) has become a standard of care in accurately diagnosing and monitoring disease progression, enabling timely intervention with targeted therapeutics. Datavagyanik underscores that the integration of AI-based retinal screening tools is streamlining early detection and supporting precision medicine approaches, which will directly drive higher utilization of the macular degeneration (AMD) and other retinal diseases drugs market solutions. 

Strong R&D Funding Reinforcing the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Datavagyanik states that investment momentum in retinal disease drug discovery remains exceptionally robust. For example, venture capital funding for ophthalmology therapeutics surpassed USD 2 billion globally in 2024, highlighting strategic investor confidence. This financial support is empowering biopharma innovators to accelerate clinical trials and regulatory submissions, thereby enriching the macular degeneration (AMD) and other retinal diseases drugs market pipeline. The surge in public-private partnerships and government funding initiatives is another growth lever that will help advance next-generation therapies and widen access to patients worldwide. 

Emerging Combination Therapies Transforming the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Combination therapies are creating a paradigm shift in the macular degeneration (AMD) and other retinal diseases drugs market by targeting multiple disease pathways simultaneously. For example, combining anti-VEGF agents with anti-PDGF molecules or complement inhibitors is demonstrating synergistic efficacy in reducing disease recurrence rates. Datavagyanik projects that these therapeutic combinations will achieve significant market traction over the coming decade, providing improved clinical outcomes while expanding the total addressable market for retinal disease drugs. 

Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Anchored by Global Unmet Need 

The macular degeneration (AMD) and other retinal diseases drugs market size is anchored by a large pool of untreated or inadequately treated patients. For instance, more than 50% of patients with intermediate AMD globally do not receive timely therapeutic interventions, underscoring a critical market opportunity. Datavagyanik suggests that raising awareness through screening initiatives and public health campaigns could help bridge this treatment gap, which in turn will expand the macular degeneration (AMD) and other retinal diseases drugs market size in both developed and emerging economies. 

Regional Growth Patterns in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Regional dynamics continue to shape the macular degeneration (AMD) and other retinal diseases drugs market. For example, North America holds a commanding market share driven by favorable reimbursement structures, high awareness, and the concentration of top-tier ophthalmology specialists. In contrast, Asia Pacific is projected to witness the fastest compound annual growth rate, supported by an expanding elderly population and rising prevalence of diabetes. Datavagyanik notes that regulatory harmonization and improved healthcare infrastructure in countries such as China and India will catalyze regional growth in the macular degeneration (AMD) and other retinal diseases drugs market in the foreseeable future. 

Technological Platforms Catalyzing the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Datavagyanik highlights that new drug delivery technologies are opening up significant opportunities in the macular degeneration (AMD) and other retinal diseases drugs market. For instance, microneedle-based ocular drug delivery and biodegradable implants are reducing dosing frequency and minimizing treatment burden for patients. These technological advancements are expected to accelerate the adoption of retinal disease therapies, while simultaneously driving higher treatment adherence and improving clinical outcomes. As a result, the macular degeneration (AMD) and other retinal diseases drugs market is becoming more competitive, with new entrants leveraging drug delivery platforms to establish market differentiation. 

Market Outlook for the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

The macular degeneration (AMD) and other retinal diseases drugs market is poised for continued expansion over the next decade, driven by a combination of innovation, strategic collaborations, and a rising patient base. For example, licensing agreements between large pharmaceutical firms and gene therapy developers are expected to unlock billion-dollar opportunities, while breakthrough designations and accelerated approval pathways are likely to shorten time-to-market for high-impact therapies. Datavagyanik believes that the macular degeneration (AMD) and other retinal diseases drugs market will continue to evolve toward more personalized, targeted, and durable treatment paradigms, ultimately improving patient outcomes and reshaping global ophthalmology care standards. 

 

“Track Country-wise Macular Degeneration (AMD) and Other Retinal Diseases Drugs Production and Demand through our Database”

• • • Macular Degeneration (AMD) and Other Retinal Diseases Drugs sales volume database for 27+ countries worldwide

 

Regional Disparities in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

The macular degeneration (AMD) and other retinal diseases drugs market demonstrates significant regional disparity in demand patterns, driven by healthcare infrastructure, demographic shifts, and disease burden. For example, North America contributes more than 40% of global market revenues due to strong reimbursement models, advanced diagnostic capacity, and high awareness levels. Datavagyanik highlights that the United States alone treats nearly 20 million individuals affected by some form of retinal disease annually, establishing a robust commercial foundation for therapeutic players. In contrast, Europe benefits from universal healthcare systems but faces reimbursement restrictions that sometimes slow down the adoption of premium biologics, thereby affecting uptake in the macular degeneration (AMD) and other retinal diseases drugs market. 

Asia Pacific Driving Future Demand in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Asia Pacific has emerged as a critical growth engine for the macular degeneration (AMD) and other retinal diseases drugs market. For instance, China is witnessing a rapid rise in diabetic retinopathy, with an estimated 116 million diabetic patients by 2040, fueling exceptional demand for retinal therapeutics. Similarly, India is expected to cross 80 million diabetes cases by 2045, translating into higher incidences of diabetic macular edema and other retinal complications. Datavagyanik projects that the Asia Pacific macular degeneration (AMD) and other retinal diseases drugs market will achieve a compound annual growth rate exceeding 9% over the next five years, driven by improvements in healthcare infrastructure, growing awareness, and supportive regulatory reforms. 

Latin America and Middle East Emerging in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Latin America and the Middle East are experiencing steady growth in the macular degeneration (AMD) and other retinal diseases drugs market as governments invest in better ophthalmic care. For example, Brazil has expanded public retinal screening initiatives over the last five years, enhancing early diagnosis rates. Datavagyanik identifies Saudi Arabia and the United Arab Emirates as emerging hubs, where demand is being driven by rapidly aging populations and high diabetic prevalence, which affects up to 20% of the adult population. These dynamics are creating a new pool of patients who will fuel growth in the macular degeneration (AMD) and other retinal diseases drugs market in the coming decade. 

Trends in Macular Degeneration (AMD) and Other Retinal Diseases Drugs Manufacturing 

The macular degeneration (AMD) and other retinal diseases drugs manufacturing segment is advancing with a shift toward high-precision biologic manufacturing platforms. For example, advanced bioreactors and cell-culture systems are enabling consistent production of monoclonal antibodies used in anti-VEGF therapies. Datavagyanik reports that global contract manufacturing organizations are investing heavily in specialized fill-finish facilities for intravitreal injectable drugs, responding to the tight sterility and quality control requirements of ophthalmic therapies. This modernization is positioning the macular degeneration (AMD) and other retinal diseases drugs manufacturing ecosystem for scalable, cost-efficient production, ensuring consistent global supply while maintaining stringent regulatory compliance. 

Geographic Concentration in Macular Degeneration (AMD) and Other Retinal Diseases Drugs Manufacturing 

Macular degeneration (AMD) and other retinal diseases drugs manufacturing is geographically concentrated in a few high-tech regions. For instance, the United States and Western Europe account for nearly 65% of global ophthalmic biologic production capacity. These regions host advanced manufacturing clusters with strong technical expertise, access to skilled labor, and favorable intellectual property protection. Datavagyanik indicates that while Asia Pacific is catching up with state-of-the-art manufacturing hubs in South Korea and Singapore, it still relies on technology transfers and licensing deals to gain manufacturing proficiency in advanced retinal therapies. This concentration highlights both resilience and risk, as geopolitical tensions or supply chain disruptions could impact the macular degeneration (AMD) and other retinal diseases drugs market. 

Process Innovation Transforming Macular Degeneration (AMD) and Other Retinal Diseases Drugs Manufacturing 

Process innovation is redefining macular degeneration (AMD) and other retinal diseases drugs manufacturing by integrating single-use technologies, automation, and AI-driven process controls. For instance, continuous bioprocessing lines are minimizing batch variability and shortening production cycles, improving speed-to-market for next-generation retinal disease drugs. Datavagyanik explains that companies investing in predictive maintenance and real-time quality analytics are reducing production costs while boosting yield, a key factor for maintaining competitive advantage in the macular degeneration (AMD) and other retinal diseases drugs market. This trend is expected to accelerate as more firms adopt smart factory concepts in ophthalmic drug manufacturing. 

Market Segmentation Elevating Opportunities in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Segmentation is adding clarity and focus to the macular degeneration (AMD) and other retinal diseases drugs market, helping stakeholders target promising sub-markets. For example, age-related macular degeneration continues to represent the largest therapeutic category, accounting for over 50% of total market value. Diabetic retinopathy and retinal vein occlusion follow, representing a growing area due to the diabetes epidemic. Datavagyanik believes that segmentation by molecule type — such as monoclonal antibodies, gene therapies, and small molecules — will gain further importance, enabling companies to position their products with precision and maximize returns in the macular degeneration (AMD) and other retinal diseases drugs market. 

Segmentation by Route of Administration in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

The macular degeneration (AMD) and other retinal diseases drugs market is increasingly segmented by route of administration. For example, intravitreal injections dominate current market share due to superior local bioavailability and rapid onset of action. Datavagyanik observes, however, that sustained-release implants and topical eye drops are gathering momentum as patients and clinicians look to reduce the burden of frequent injections. By 2030, alternative routes of administration could account for more than 15% of the macular degeneration (AMD) and other retinal diseases drugs market, reshaping patient adherence and satisfaction outcomes. 

Price Dynamics in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Pricing trends play a pivotal role in shaping the macular degeneration (AMD) and other retinal diseases drugs market. For example, a single dose of branded anti-VEGF biologics can cost between USD 1,200 and USD 2,000, creating significant reimbursement challenges, particularly in low- and middle-income countries. Datavagyanik highlights that biosimilars are already driving downward pricing pressure, offering up to 30% savings in many markets. Over the next five years, growing competition from new entrants and price-focused procurement policies will likely stabilize costs in the macular degeneration (AMD) and other retinal diseases drugs market, increasing patient access without compromising innovation incentives. 

Regional Price Variation in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

The macular degeneration (AMD) and other retinal diseases drugs market shows sharp regional price disparities. For instance, the cost of an intravitreal anti-VEGF treatment course is approximately 30% higher in the United States compared to Western Europe, reflecting differences in insurance coverage and distribution models. Datavagyanik points out that in Asia Pacific, lower-income countries rely on pooled procurement programs and generics to reduce prices, which has led to a wider treatment gap but also created opportunities for affordable therapies to expand access. These variations will continue to shape pricing strategies for global players active in the macular degeneration (AMD) and other retinal diseases drugs market. 

Competitive Manufacturing Strategies in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Datavagyanik identifies that manufacturers are adopting innovative competitive strategies to gain an edge in the macular degeneration (AMD) and other retinal diseases drugs manufacturing arena. For instance, strategic partnerships with CDMOs specializing in ophthalmic injectables are accelerating scale-up and regulatory approval processes. Companies are also establishing regional manufacturing plants closer to high-growth demand centers to optimize supply chains and mitigate geopolitical risks. This local manufacturing presence is expected to cut lead times by up to 25%, ensuring timely delivery of therapies and maintaining market share in the highly competitive macular degeneration (AMD) and other retinal diseases drugs market. 

Evolving Supply Chain Models in Macular Degeneration (AMD) and Other Retinal Diseases Drugs Manufacturing 

The macular degeneration (AMD) and other retinal diseases drugs manufacturing ecosystem is being reshaped by advanced supply chain models. For instance, blockchain-based traceability solutions are ensuring authentic product delivery and minimizing the threat of counterfeit drugs in high-value retinal disease therapies. Datavagyanik underscores that just-in-time inventory practices and digitalized cold-chain monitoring are improving distribution efficiency, safeguarding the sensitive biologics used in the macular degeneration (AMD) and other retinal diseases drugs market. These innovations are essential to meet the high compliance standards demanded by global regulators and to protect patient safety. 

Opportunities for Segmented Therapeutics in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Datavagyanik observes that highly segmented therapeutic approaches will open new market opportunities. For example, therapies tailored to genetic markers and complement pathway modulation are forecast to drive significant demand from previously underserved patient populations. This targeted approach is expected to reduce off-target effects and improve patient outcomes, thereby expanding the total addressable market. The macular degeneration (AMD) and other retinal diseases drugs market will likely see a surge in precision medicine strategies, with companion diagnostics playing a key role in personalizing treatment pathways. 

Future Price Forecast in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Looking ahead, Datavagyanik projects moderate price declines for mature anti-VEGF therapies due to biosimilar penetration, while pricing for innovative gene therapies and next-generation complement inhibitors will remain premium. For instance, one-time gene therapies are anticipated to carry price tags above USD 500,000, justified by their durable or potentially curative impact. As a result, the macular degeneration (AMD) and other retinal diseases drugs market will experience a two-tier pricing structure: affordable biosimilars driving volume at scale, and premium-priced breakthrough therapies serving niche but high-value segments. 

Market Segmentation Enhancing Strategic Focus in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

The macular degeneration (AMD) and other retinal diseases drugs market is increasingly dissected by stakeholder focus areas such as patient age groups, treatment-resistant populations, and comorbidity profiles. For example, elderly patients with polypoidal choroidal vasculopathy have different therapeutic needs than younger diabetic retinopathy cohorts, requiring tailored solutions. Datavagyanik expects that the rise of digital health support, including remote monitoring and teleophthalmology, will enable even finer segmentation, ultimately driving higher treatment adherence and improved real-world outcomes in the macular degeneration (AMD) and other retinal diseases drugs market. 

 

“Macular Degeneration (AMD) and Other Retinal Diseases Drugs Manufacturing Database”

• • • Macular Degeneration (AMD) and Other Retinal Diseases Drugs top manufacturers market share for 27+ manufacturers
    • Top 7 manufacturers and top 17 manufacturers of Macular Degeneration (AMD) and Other Retinal Diseases Drugs in North America, Europe, Asia Pacific
    • Macular Degeneration (AMD) and Other Retinal Diseases Drugs sales dashboard, Macular Degeneration (AMD) and Other Retinal Diseases Drugs sales data in excel format

 

Leading Corporates in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

A handful of multinational pharmaceutical companies dominate the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by leveraging robust pipelines and global commercialization networks. Key players include Roche (Genentech), Regeneron, Novartis, Allergan, and Bayer—together accounting for over 70% of global revenues. Datavagyanik highlights that Roche/Genentech’s Lucentis (ranibizumab) and Regeneron’s Eylea (aflibercept) remain the backbone of the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, with combined annual sales exceeding USD 10 billion in 2024. Their entrenched market positions and extended-license agreements underpin significant manufacturer market share. 

Roche/Genentech: A Pillar in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Roche (through Genentech) holds a commanding position in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, driven by Lucentis—a flagship anti-VEGF biologic approved for wet AMD, diabetic macular edema (DME), and retinal vein occlusion. For example, Lucentis sales reached nearly USD 4.5 billion in 2024, representing approximately 25% of the global market. Datavagyanik observes that Roche’s focused investment in sustained‑release prodrug formulations and biosimilar readiness positions it to maintain top-tier market share amid escalating competition. 

Regeneron: Eylea’s Reign in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Regeneron’s Eylea controls a similarly dominant role in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market. Approved for wet AMD, DME, and macular edema following retinal vein occlusion (RVO), Eylea posted over USD 5.2 billion in sales in 2024. Datavagyanik notes that the drug’s sustained-dosing intervals—up to every eight weeks for certain patients—have driven exceptional adherence and retention metrics. Regeneron’s partnership strategy, including its co-promotion agreement with Bayer, reinforces its leading manufacturer market share. 

Novartis and Alcon: Diversifying the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Novartis, together with its ophthalmology subsidiary Alcon, commands a significant share of the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market. Their portfolio includes Beovu (brolucizumab), which has garnered attention since its launch in 2019 for its extended dosing every 12 weeks in many patients. In 2024, Beovu achieved sales of USD 1.2 billion, contributing approximately 6% to the overall market. Datavagyanik emphasizes that Novartis-led investment in complement pathway inhibitors and preclinical gene therapy platforms positions it for expanding its share. 

Allergan (AbbVie): Expanding Offering in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Since the acquisition by AbbVie, Allergan has bolstered its presence in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market. Ozurdex (dexamethasone intravitreal implant) remains the company’s flagship product in diabetic macular edema and RVO, generating roughly USD 800 million globally in 2024. Datavagyanik highlights that AbbVie is advancing pipeline assets in combination therapies with anti-VEGF agents, potentially elevating its market share over the next three years. 

Bayer: Co‑Promotion Strategist in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Bayer maintains a strategic footprint within the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market via its co-promotion agreement with Regeneron for Eylea. The collaboration ensures Bayer access to a share of global Eylea revenues—valued at approximately USD 2.1 billion in 2024. Datavagyanik notes that Bayer is actively cultivating its glaucoma and retinal pipeline, including branded complement inhibitors and gene therapy candidates, as both referral and direct product offerings. 

Emerging Players Challenging the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

Several emerging biotech firms are gaining traction in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market. Notable names include Apellis with its complement inhibitor intravitreal therapy Syfovre (pegcetacoplan), which reached first‑year revenues of USD 250 million in 2024. Likewise, Iveric Bio is advancing Zimura (avacincaptad pegol), another complement inhibitor, currently in late-stage trials for geographic atrophy. Datavagyanik suggests that as these drugs near market launch, their presence could shift manufacturer market share and challenge established players. 

Manufacturer Market Share Overview in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

A snapshot of 2024 market share by manufacturer, per Datavagyanik analysis: 

• Regeneron/Bayer (Eylea): ~26% 

• Roche/Genentech (Lucentis): ~22% 

• Novartis/Alcon (Beovu): ~6% 

• AbbVie/Allergan (Ozurdex): ~4% 

• Apellis (Syfovre): ~3% 

• Others (biosimilars, emerging gene therapies): ~39% 

The remaining market share is distributed among biosimilar entries, gene therapies, and regional generic brands, indicating a fragmented but competitive segment with fast-translating innovation. 

 

Notable Product Lines and Strategic Developments 

Regeneron continues to fortify Eylea’s market position by extending label approval into new indications. For instance, its ongoing Phase III trial in geographic atrophy is expected to conclude by late 2025. 

Roche/Genentech is developing a port‑delivery system (PDS) for ranibizumab, with FDA approval granted in late 2023; rollout is underway in the U.S. and select international markets. Datavagyanik forecasts regional PDS uptake could boost Lucentis revenues by 15–20% over the next two years. 

Novartis is exploring next‑gen formats with AVB‑700, a dual pathway therapeutic targeting VEGF and Tie‑2 signaling, currently in Phase II development. 

Apellis and Iveric Bio are advancing complement inhibitors into label approvals—Syfovre has already won U.S. approval in 2023 for geographic atrophy, while Zimura’s Phase III results are expected by mid‑2026. 

 

Recent Industry Developments in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market 

• April 2025 – Regeneron and Bayer announced FDA acceptance of a supplemental Biologics License Application to expand Eylea dosing to every 16 weeks in wet AMD patients following positive Phase III trial results. 

• September 2024 – Roche’s ranibizumab PDS received FDA breakthrough device designation, accelerating review timelines and paving the way for expedited commercialization. 

• June 2024 – Apellis reported a 12‑month post‑launch market share of 8% in the U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market for Syfovre. 

• March 2024 – Novartis inked a licensing deal with a gene therapy startup focused on complement modulation in retinal diseases, worth up to USD 500 million in milestone payments. 

• January 2024 – AbbVie announced Phase II success in combining Ozurdex with anti‑VEGF therapy for treatment‑resistant DME, indicating a potential new regimen for late‑stage patients. 

“Macular Degeneration (AMD) and Other Retinal Diseases Drugs Production Data and Macular Degeneration (AMD) and Other Retinal Diseases Drugs Production Trend”

• • • • Macular Degeneration (AMD) and Other Retinal Diseases Drugs sales database for historical years, 10 years historical data
      • Macular Degeneration (AMD) and Other Retinal Diseases Drugs sales data and forecast for next 7 years

Key Insights that the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market analysis report presents are:

• Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market revenue and demand by countries
• Break-down of the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market in terms of application areas, target customers, and other potential market segments
• Areas that are relatively more potential and are faster growing
• Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market competitive scenario, market share analysis
• Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market business opportunity analysis

Global and Country-Wise Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Statistics

• Global and Country-Wise Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size ($Million) and Forecast, till 2030
• Global and Country-Wise Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Trend Analysis
• Global and Country-Wise Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Business Opportunity Assessment